News

Venetoclax and Hypomethylating Agent Treatment Shows Efficacy for R/R Acute Myeloid Leukemia, With Genetic Predictors of Response Identified

02/28/2025

Emily Estrada

Venetoclax plus hypomethylating agents demonstrated efficacy for treating R/R AML, with genetic features, including distinct mutations, predicting response to treatment, according to a retrospective study.

Venetoclax plus hypomethylating...

02/28/2025

Oncology

News

Autologous Hematopoietic Stem Cell Transplantation as Additional Treatment Option for Secondary Acute Myeloid Leukemia

02/28/2025

Emily Estrada

While allogeneic hematopoietic stem cell transplantation is the standard treatment for secondary AML, autologous hematopoietic stem cell transplantation shows promising outcomes as an additional treatment option, according to a retrospective...

While allogeneic hematopoietic...

02/28/2025

Oncology

FDA Approval

FDA Approves Treosulfan With Fludarabine for Patients With AML or MDS Prior to AlloHSCT

02/07/2025

Emily Estrada

On January 21, 2025, the FDA approved treosulfan with fludarabine prior to allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome.

On January 21, 2025, the FDA...

02/07/2025

Oncology

News

Midostaurin Plus CLAG-M Yields Comparable Results to Midostaurin Plus 7+3 Therapy, High Remission Rates Among Patients With FLT3-Mutated AML

01/31/2025

Emily Estrada

For patients with AML and FLT3 mutation, treatment with midostaurin combined with cladribine, high-dose cytarabine, GCSF, and mitoxantrone is as safe and effective as midostaurin combined with standard therapy, according to a retrospective...

For patients with AML and FLT3...

01/31/2025

Oncology

News

Venetoclax Plus Hypomethylating Agents Demonstrated Improved Outcomes and Infection Risk Among Older Patients With Acute Myeloid Leukemia

01/31/2025

Emily Estrada

Venetoclax combined with hypomethylating agents for the treatment of acute myeloid leukemia improved infection rates and outcomes among patients, as compared to other chemotherapies, according to a retrospective analysis.

Venetoclax combined with...

01/31/2025

Oncology

News

Relationship Between BCL-2 Expression and Venetoclax Concentration Among Patients With AML

01/24/2025

Emily Estrada

Higher levels of BCL-2 expression at time of diagnosis may be associated with worse outcomes while higher blood concentrations of venetoclax may have an impact on timing of adverse reactions among patients with AML, according to a recent...

Higher levels of BCL-2...

01/24/2025

Oncology

News

Pevonedistat and Belinostat Therapy Demonstrates Safety, Modest Activity for Patients With R/R Acute Myeloid Leukemia or High-Risk MDS

01/24/2025

Emily Estrada

According to results from a dose escalation phase 1 study, combination belinostat and pevonedistat therapy for relapsed/refractory acute myeloid leukemia or high-risk MDS demonstrated some activity and limited toxicity.

According to results from a dose...

01/24/2025

Oncology

News

Olutasidenib and Azacitidine Show Efficacy and Durability for Treatment of R/R mIDH1 Acute Myeloid Leukemia

01/24/2025

Emily Estrada

Olutasidenib and azacitidine combination therapy for relapsed/refractory acute myeloid leukemia demonstrated durable patient responses and safety.

Olutasidenib and azacitidine...

01/24/2025

Oncology

News

FDA Grants Approval to Revumenib for Patients With R/R Acute Leukemia With KMT2A Translocation

11/17/2024

On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.

On November 15, 2024, the FDA...

11/17/2024

Oncology

News

Gilteritinib Following AlloHCT Shows No Improvement in Health-Related Quality of Life Among Patients With FLT3-ITD AML

10/31/2024

Gilteritinib maintenance therapy following allogeneic hematopoietic cell transplantation among patients with FLT3-ITD acute myeloid leukemia was not associated with any difference in health-related quality of life when compared with a...

Gilteritinib maintenance therapy...

10/31/2024

Oncology

Recent News

News

Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma

04/02/2025

Emily Estrada

At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.

At a tolerable and safe dose,...

04/02/2025

Oncology

News

Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma

04/02/2025

Emily Estrada

Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.

Quadruplet therapy with...

04/02/2025

Oncology

News

Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma

04/02/2025

Emily Estrada

The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.

The presence of 2 or more...

04/02/2025

Oncology

News

Pembrolizumab Plus Bevacizumab Shows Promise Among Previously Untreated Patients With Melanoma Brain Metastases

04/01/2025

Stephanie Holland

According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.

According to results from a...

04/01/2025

Oncology

News

Outcomes Without Adjuvant Radioactive Iodine Among Pediatric Patients With Papillary Thyroid Cancer

04/01/2025

Allison Casey

According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.

According to a retrospective...

04/01/2025

Oncology

News

Lenvatinib Plus High-Dose Radioiodine Therapy Shows Promise for Patients With Metastatic Well-Differentiated Thyroid Cancer

04/01/2025

Allison Casey

A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.

A study found the addition of...

04/01/2025

Oncology

News

Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors

03/31/2025

Janelle Bradley

Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.

Findings from a phase 2 study...

03/31/2025

Oncology

FDA Approval

Durvalumab Approved for Muscle Invasive Bladder Cancer

03/31/2025

Allison Casey

The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.

The US FDA approved neoadjuvant...

03/31/2025

Oncology

FDA Approval

FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer

03/28/2025

Stephanie Holland

Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...

Based on results from the...

03/28/2025

Oncology

FDA Approval

FDA Approves Cabozantinib for Patients With Locally Advanced or Metastatic Well-Differentiated pNETs and epNETs

03/26/2025

Stephanie Holland

Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...

Based on results from the...

03/26/2025

Oncology